Q-omics provides the consensus-scored LINC02549 profile across patient tissues and cancer cell-line models. LINC02549 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC02549 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, LINC02549 RNA expression shows 6,506 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, HNSC, and STAD as cancer lineages where LINC02549 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02549 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02549 survival associations across molecular data types. LINC02549 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02549 RNA expression–survival associations across cancer types. High LINC02549 expression shows unfavorable associations in BLCA, HNSC, LGG, STAD, KIRP and ACC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC02549 RNA expression.
This table summarizes LINC02549 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02549. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02549 shows lower tumor expression in HNSC and higher tumor expression in THCA, LUAD and KIRP. The HNSC box plot shows higher LINC02549 RNA expression in normal versus tumor tissue (log2 FC = −0.113, t-test p = .005).
This table shows molecular features associated with LINC02549 in patient tissues and cancer cell lines. In patient samples, LINC02549 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
